Table 1

Baseline demographic and disease characteristics of patients treated with biological DMARD following rituximab treatment

Characteristic*All patients receiving another biological DMARD after rituximab (n  =  185)
Age, years (SD)51.2 (12.3)
Female, n (%)145 (78.4%)
RA disease duration, years (SD)11.9 (9.2)
Previous DMARD,† n (SD)4.0 (2.4)
Previous TNF inhibitors, n (SD)1.3 (0.9)
Swollen joint count, n (SD)24.5 (13.0)
Tender joint count, n (SD)37.8 (15.9)
C-reactive protein, mg/dl (SD)3.7 (4.1)
DAS28-ESR (SD)7.0 (0.9)
  • *Mean values are reported when applicable. †Excludes methotrexate.

  • DAS28, disease activity score based on 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; TNF, tumour necrosis factor.